Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.41 |
| ▸ | WDR5 | P61964 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8738948 | 0.89 | ALDH1A1 (0.55) | HTR2AHTR2CPDK1PDK2PDK3 | |
| SCHEMBL15445211 | 0.85 | XIAP (0.42) | HTR2AHTR2CPDK1PDK2PDK3 | |
| SCHEMBL19819225 | 0.83 | ALDH1A1 (0.39) | MAPTALDH1A1MEN1GAAHPGD | |
| SCHEMBL25450201 | 0.83 | LMNA (0.38) | HTR2AHTR2CPDK1PDK2PDK3 | |
| SCHEMBL23316743 | 0.81 | NOTUM (0.34) | HTR2AHTR2CPDK1PDK2PDK3 | |
| SCHEMBL22579491 | 0.80 | HTR2A (0.42) | HTR2AHTR2CPDK1PDK2PDK3 | |
| SCHEMBL13340932 | 0.80 | NOTUM (0.47) | HTR2AHTR2CPDK1PDK2PDK3 | |
| SCHEMBL26700312 | 0.80 | TDP1 (0.38) | PDK1PDK2PDK3PDK4MAPT | |
| SCHEMBL12376502 | 0.79 | LMNA (0.38) | PDK1PDK2PDK3PDK4ALDH1A1 | |
| SCHEMBL15341900 | 0.78 | WDR5 (0.49) | HTR2AHTR2CMAPTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702409-B2 | Pyrazolyl derivatives useful as anti-cancer agents | NOVARTIS AG (CH) | 2023-07-18 | — | — | US | disclosed |
| US-11634425-B2 | Pharmaceutical compounds | PFIZER INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20230110648-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| EP-3265083-B1 | SUBSTITUTED UREA DEPSIPEPTIDE ANALOGS AS ACTIVATORS OF THE CLPP ENDOPEPTIDASE | ST JUDE CHILDRENS RES HOSPITAL (US) | 2022-07-06 | — | — | EP | disclosed |
| US-10822377-B2 | Substituted urea depsipeptide analogs as activators of the ClpP endopeptidase | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2020-11-03 | — | — | US | disclosed |
| US-10676510-B2 | Substituted urea depsipeptide analogs as activators of the ClpP endopeptidase | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2020-06-09 | — | — | US | disclosed |
| US-20200031872-A1 | Substituted Urea Depsipeptide Analogs as Activators of the CLPP Endopeptidase | ST. JUDE CHILDREN'S RESEARCH HOSPITAL | 2020-01-30 | — | — | US | disclosed |
| US-10457707-B2 | Substituted urea depsipeptide analogs as activators of the CLPP endopeptidase | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2019-10-29 | — | — | US | disclosed |
| US-10206931-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20190048040-A1 | Substituted Urea Depsipeptide Analogs as Activators of the CLPP Endopeptidase | ST JUDE CHILDRENS RES HOSPITAL (US) | 2019-02-14 | — | — | US | disclosed |
| US-20170312292-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | WUXI APPTEC (SHANGHAI) CO. LTD (CN) | 2017-11-02 | — | — | US | disclosed |
| WO-2017044858-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-03-16 | — | — | WO | disclosed |
| US-20160200770-A1 | SUBSTITUTED UREA DEPSIPEPTIDE ANALOGS AS ACTIVATORS OF THE CLPP ENDOPEPTIDASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-07-14 | — | — | US | disclosed |
| US-8993585-B2 | Cyclic amine substituted pyrimidinediamines as PKC inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| WO-2015031871-A1 | SUBSTITUTED UREA DEPSIPEPTIDE ANALOGS AS ACTIVATORS OF THE CLPP ENDOPEPTIDASE | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2015-03-05 | — | — | WO | disclosed |
| US-8436016-B2 | Fused heterocyclic M1 receptor positive allosteric modulators | Merck, Sharp & Dohme, Corp. | 2013-05-07 | — | — | US | disclosed |
| US-20110201607-A1 | FUSED HETEROCYCLIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Merck, Sharp & Dohme, Corp. | 2011-08-18 | — | — | US | disclosed |
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
| WO-2010047990-A1 | FUSED HETEROCYCLIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2010-04-29 | — | — | WO | disclosed |
| US-20100087382-A1 | Inhibitors of Hepatitis C NS3 Protease | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200770-A1 | SUBSTITUTED UREA DEPSIPEPTIDE ANALOGS AS ACTIVATORS OF THE CLPP ENDOPEPTIDASE | CLPP, DNPEP, PEPD | HTR2A 3933/4885HTR2C 4194/4885PDK1 2836/4885 |
| US-20100087382-A1 | Inhibitors of Hepatitis C NS3 Protease | RNASE1, GTF3C3, CTRL | HTR2A 1735/4885HTR2C 1526/4885PDK1 2279/4885 |
| US-11702409-B2 | Pyrazolyl derivatives useful as anti-cancer agents | PAK5, CYP51A1, SF3B5 | HTR2A 4741/4885HTR2C 4458/4885PDK1 74/4885 |
| US-10457707-B2 | Substituted urea depsipeptide analogs as activators of the CLPP endopeptidase | CLPP, DNPEP, PEPD | HTR2A 3933/4885HTR2C 4194/4885PDK1 2836/4885 |
| US-10822377-B2 | Substituted urea depsipeptide analogs as activators of the ClpP endopeptidase | CLPP, DNPEP, PEPD | HTR2A 3933/4885HTR2C 4194/4885PDK1 2836/4885 |
| US-20110201607-A1 | FUSED HETEROCYCLIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, OPRM1 | HTR2A 105/4885HTR2C 97/4885PDK1 2650/4885 |
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | PRKCH, PKD2, PRKCQ | HTR2A 2713/4885HTR2C 2391/4885PDK1 80/4885 |
| US-20230110648-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | HTR2A 3185/4885HTR2C 1754/4885PDK1 2075/4885 |
| US-20190048040-A1 | Substituted Urea Depsipeptide Analogs as Activators of the CLPP Endopeptidase | CLPP, DNPEP, PEPD | HTR2A 3933/4885HTR2C 4194/4885PDK1 2836/4885 |
| US-20170312292-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, CREBBP, HDAC1 | HTR2A 4312/4885HTR2C 4336/4885PDK1 723/4885 |
| US-10206931-B2 | Therapeutic compounds and uses thereof | EP300, CREBBP, HDAC1 | HTR2A 4312/4885HTR2C 4336/4885PDK1 723/4885 |
| US-11634425-B2 | Pharmaceutical compounds | GABRA6, CHRNA6, CNR1 | HTR2A 1333/4885HTR2C 786/4885PDK1 3937/4885 |
| US-10676510-B2 | Substituted urea depsipeptide analogs as activators of the ClpP endopeptidase | PREP, PRCP, CLPP | HTR2A 3446/4885HTR2C 3889/4885PDK1 2203/4885 |
| US-20200031872-A1 | Substituted Urea Depsipeptide Analogs as Activators of the CLPP Endopeptidase | CLPP, DNPEP, PEPD | HTR2A 3933/4885HTR2C 4194/4885PDK1 2836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.